These results further illustrated the mechanism of the ATRX/PARP1 axis contributing to TMZ resistance (Figure 7) and provided substantial new evidence that PARP inhibitor might be a potential adjuvant agent in overcoming TMZ resistance in glioma. The gene discussed is PARP1; the disease is central nervous system cancer.